Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-09-2009 | Original Article

A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer

Authors: Vasiliki Bozionelou, Kostas Kalbakis, Lambros Vamvakas, Sofia Agelaki, Nikolaos Androulakis, Antonia Kalykaki, Vassilis Georgoulias, Dimitris Mavroudis

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Objective

To determine the maximum tolerated doses (MTDs) and dose limiting toxicities (DLTs) of gemcitabine (GEM), docetaxel (DOC) and carboplatin (CARBO) combination.

Patients and methods

A total of 33 previously untreated HER-2 negative patients with stage IIIB-IV breast cancer received escalated doses of GEM, DOC and CARBO all given sequentially on day 1 every 2 weeks. Twenty-three patients (70%) had previously received adjuvant or neoadjuvant chemotherapy.

Results

The recommended MTDs are GEM 1,500 mg/m2, DOC 50 mg/m2 and CARBO 3AUC. Seven dose levels were evaluated and neutropenia was the primary dose-limiting event. Of 319 chemotherapy cycles delivered, grade 3–4 neutropenia occurred in 13.5% of them with two cases of febrile neutropenia. Diarrhea and asthenia were the most common non-hematological toxicities. Three (16%) complete and 6 (32%) partial responses were observed among 19 patients with measurable disease.

Conclusion

The biweekly administration of GEM, DOC and CARBO is a well-tolerated regimen which merits further evaluation.
Literature
1.
Vogel CL, Azevedo S, Hilsenbeck S et al (1992) Survival after first recurrence of breast cancer: The Miami experience. Cancer 70:129–135PubMedCrossRef
2.
Hayes DF, Henderson IC, Shapiro CL (1995) Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 22(Suppl 5):5–21PubMed
3.
Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24/4(Suppl 13):11–18
4.
Ravdin PM (1997) Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Semin Oncol 24/4(Suppl 10):18–21
5.
Bissery MC, Guenard D, Gueritte-Voegelein F et al (1991) Experimental antitumor activity of Taxotere (RPR56976, NSC628503) a taxol analogue. Cancer Res 51:4845–4852PubMed
6.
Carmichael J, Walling J (1997) Advanced breast cancer: investigational role of gemcitabine. Eur J Cancer 33(Suppl 1):S27–S30PubMedCrossRef
7.
Carmichael J, Possinger K, Phillip P et al (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731–2736PubMed
8.
Colomer R (2004) Gemcitabine and paclitaxel in metastatic breast cancer: a review. Oncology 18(14 Suppl 12):8–12PubMed
9.
Albain KS, Nag SM, Calderillo-Riuz G et al (2008) Gemcitabine plus paclitaxel (GT) vs paclitaxel (T) monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26(24):3950–3957PubMedCrossRef
10.
Crown J (2001) The platinum agents: a role in breast cancer treatment? Semin Oncol 28/1(Suppl 3):28–37CrossRef
11.
Spielmann M, Llombart-Cussac A, Zelek L et al (1990) Docetaxel-cisplatin combination chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 10:1457–1460CrossRef
12.
Mavroudis D, Malamos N, Alexopoulos A et al (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol 10:211–215PubMedCrossRef
13.
Mavroudis D, Malamos N, Polyzos A et al (2004) Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: A multicenter phase II study. Oncology 67:250–256PubMedCrossRef
14.
Fountzilas G, Nikolaides C, Bafaloukos D et al (2000) Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest 18:503–509PubMedCrossRef
15.
Laufman LR, Spiridonidis CH, Pritchard J et al (2001) Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 12:1259–1264PubMedCrossRef
16.
Brandi M, Vici P, Lopez M et al (2004) Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 31(2 Suppl 5):13–19PubMedCrossRef
17.
Kornek GV, Haider K, Kwasny W et al (2002) Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8(5):1051–1056PubMed
18.
Mavroudis D, Alexopoulos A, Malamos N et al (2003) Salvage treatment of metastatic breast cancer with docetaxel and carboplatin: a multicenter phase II trial. Oncology 64:207–212PubMedCrossRef
19.
O’ Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823CrossRef
20.
Albain KS, Nag SM, Calderillo-Ruiz G et al (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26(24):3950–3957PubMedCrossRef
21.
Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592PubMedCrossRef
22.
Geels P, Eisenhauer E, Bezjak A et al (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395–2405PubMed
23.
Gennari A, Sormani MP, Pronzato P et al (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14–20PubMedCrossRef
24.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216PubMedCrossRef
25.
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942CrossRef
26.
Vici P, Belli F, Di Lauro L et al (2001) Docetaxel in patients with anthracycline-resistant advanced breast cancer. Oncology 60:60–65PubMedCrossRef
27.
Ando M, Watanabe T, Nagata K et al (2001) Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 19:336–342PubMed
28.
Leu KM, Ostruszka LJ, Shewach D et al (2004) Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22:1706–1712PubMedCrossRef
29.
Denes AE, Needles BM, Schmidt A et al (2000) A comparison of two schedules of docetaxel in combination with gemcitabine given every other week (abstract). Proc Am Soc Clin Oncol 19:828
30.
Sanchez-Rovira P, Jaen A, Gonzalez E et al (2000) Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer. Clin Breast Cancer 1:226–232PubMedCrossRef
31.
Conte PF, Gennari A, Donati S et al (2001) Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 68:171–179PubMedCrossRef
32.
Cappuzzo F, Mazzoni F, Gennari A et al (2004) Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer 90:31–35PubMedCrossRef
33.
Zielinski C, Beslija S, Mrsic-Krmpotic Z et al (2005) Gemcitabine, Epirubicin, and Paclitaxel versus Fluorouracil, Epirubicin, and Cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective randomized phase III trial. J Clin Oncol 23:1401–1408PubMedCrossRef
34.
Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19(11):1847–1852PubMedCrossRef
Metadata
Title
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer
Authors
Vasiliki Bozionelou
Kostas Kalbakis
Lambros Vamvakas
Sofia Agelaki
Nikolaos Androulakis
Antonia Kalykaki
Vassilis Georgoulias
Dimitris Mavroudis
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-0928-6

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue

Original Article

Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer

Original Article

The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties

Original Article

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Original Article

Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice

Original Article

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

Original Article

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits